Zhitong Financial APP, Sima Ophthalmology (03309) announced that on November 24, 2021, Sima China (buyer), Shengchuang Investment (seller) and Shenzhen Aikangjian entered into a deep venture equity transfer agreement, according to which Sima China agreed to purchase the capital for sale from Shenzhen Venture Capital at a cost of RMB 45.5 million, accounting for 7.0% of the total registered capital of Shenzhen Aikangjian before the investment.

In addition, Sima China, the original seller and Shenzhen Aikangjian entered into a supplementary equity investment agreement to amend certain terms of the original equity investment agreement, however, the percentage equity acquired by Sima China under the investment and the total consideration payable by Sima China under the investment remain unchanged. Upon completion of the investment and the acquisition of Shenzhen Venture Capital, the Group will directly and indirectly hold a total of 61.5% of the issued shares of Shenzhen Aikangjian (after the capital contribution has been expanded) and will be its controlling shareholder.

According to the company, the investment is a good opportunity to take advantage of medical service expertise, Shenzhen's patient base, and Shenzhen Aikangjian's knowledge and experience in dental business to expand dental care services in Shenzhen. The directors are optimistic about the future growth potential of Shenzhen Aikangjian (especially when Hong Kong and Shenzhen may re-open customs in the near future) and therefore consider that the Group acquires the additional equity interest in Shenzhen Aikangjian at a deep venture price, in order to improve the return on the Group's investment in Shenzhen Aikangjian, which is beneficial to the Group.